Chemocentryx Inc. (CCXI) Return on Investment ROI from the second quarter of 2026 to second quarter of 2021 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Chemocentryx Inc.  (NASDAQ: CCXI)


Chemocentryx's ROI from its second quarter of 2026 to the second quarter of 2021 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Chemocentryx's ROI in the second quarter of 2026?
Chemocentryx Inc. achieved a return on average invested assets (ROI) of 61.91 % in its second quarter of 2026, this is above CCXI's average return on investment of -29.12%.
Chemocentryx Inc. invested over the 12 months ending in its second quarter of 2026 $354 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 408 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 4464 to 4581.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Investment Change TTM -2.26 % -6.94 % -21.22 % -26.35 % -23.16 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 283 419 416 298 326
Return On Investment (TTM) 61.91 % 84.87 % -39.28 % -42.17 % -36.38 %
CCXI's Overall Ranking # 4581 # 4464 # # #
Seq. Investment Change TTM -2.94 % 7.62 % 1.58 % -7.89 % -7.58 %
Seq. Net Income Change TTM -29.2 % - - - -
Net Income (TTM) in Millions 219 309 -133 -141 -132

CCXI Company Profile >> Back to CCXI Roi Comparisons >> See Annual CCXI Return On Investment



Return On Investment CCXI's Ranking
Within: No.
Industry # 161
Sector # 409
Overall # 4581

Return On Investment Statistics
High Average Low
16.03 %
-29.12 %
-66.2 %
(Dec 31 2017)   (Mar 31 2016)







Financial Statements
Chemocentryx's II. Quarter Investments $ 283 Millions CCXI's Balance sheet
Chemocentryx's II. Quarter Income $ -131 Millions Quarterly CCXI's Income Statement
CCXI's Income by Division See CCXI's Income by Division


CCXI Annual Return On Investment (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017
Total Investments in Millions 316 469 150 119 156
Y / Y Investment Growth -32.65 % 212.58 % 26.14 % -23.96 % 33.17 %
Net Income in Millions -132 -55 -55 -38 18
Y / Y Net Income Growth - - - - -
Annual Return On Investment -41.72 % -11.81 % -36.99 % -31.93 % 11.42 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CCXI's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CCXI's Competitors
Subscribers only: Roi for Chemocentryx's Suppliers
Subscribers only: Return On Investment for CCXI's Customers

Other Ratios
CCXI's Roa CCXI's Inventory Turnover Ratio CCXI's Growth Rates CCXI's Dividend Statistics
CCXI's Profitability Ratios CCXI's Asset Turnover Ratio CCXI's Dividend Growth
CCXI's Roe CCXI's Valuation Ratios CCXI's Financial Strength Ratios CCXI's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %

Date modified: 2026-09-26T07:44:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.